About
Lyfstone AS is a med-tech company developing informative and functional biomarkers for the orthopaedic market.
Our mission is to provide orthopaedic health care professionals with diagnostic tools to make better decisions and to deliver the best patient care.
We offer an easy, fast and quantitative Point of Care test (POCT) for Calprotectin in Synovial Fluid. The POCT is designed to give results within 15 minutes, and will aid in identifying the risk of prosthetic joint infection. For more information contact info@lyfstone.comLyfstone® Calprotectin for Synovial Fluid has been developed in close collaboration with Calpro AS, a Norwegian company with more than 20 years of experience in providing high quality products and solutions for Calprotectin analysis in faeces, plasma/serum samples, enabling a variety of important diagnostic insights, including the assessment of IBD and rheumatic diseases and distinguishing bacterial from viral infections.
Calpro AS is the legal manufacturer of Lyfstone® Calprotectin for Synovial Fluid.
Get in touch
Lyfstone main office
SIVA Innovasjonssenter 9294 Tromsø, Norway
Our Team
Hans Bloemendal
CEO (EU)
Finn Olav R. Elde
Chairman (EU)
Bente Pettersen
CFO (EU)
Jonathan L. Schaffer
Medical Consultant (USA)*
Jarle Mikalsen
CScO (EU)
Stein Lian
CTO (EU)
Marc Penn
COO (USA)
RK Khosla
Finance & Strategy consultant
Dirk van Hoegaerden
CSO (EU)
Anders Einung Hansen
COO (EU)
Eric Bendiksen
CLO (EU)
Stefan Pickartz
Consultant
Frans van Andel
Consultant
Thijs Bloemendal
Consultant
Gunnar Knutsen
Medical Consultant